Dr. Petrin has over 20 years experience in the pharmaceutical and biotechnology industry in the areas of drug development and medical and regulatory affairs.
Prior to joining Brighton Biotech, Dr. Petrin spent 10 years with Bristol-Myers Squibb (BMS) in Europe and the US, first as Medical Director for Eastern Europe, later as Executive Director and finally Vice President for Intercontinental Regulatory Science. He participated in several key committees either as a member or in leadership roles (Full and Early Development Operating Committees at the Pharmaceutical Research Institute (member); Senior Leadership Team, Regulatory Science and Outcomes Research (member); Corporate Labeling Committee of the Worldwide Medicines Group (member); Life Cycle Management Committee, Chair of the Special Task Force On Global Regulatory Strategy (co-chair); Special Task Force On Mapping and Improvement of Global Regulatory Practices (chair); Special Task Force On Strategic Globalization of the Pharmaceutical Research Institute (chair)).
While at BMS, he was a member of the Asia Pacific Technical Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), and represented PhRMA at the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & (IFPMA).
In 2001, he founded Pharmaceutical Regulatory Services, Inc., a specialized drug development advisory firm, based in Princeton, NJ, which offers its clients support in close to 90 countries.
Dr. Petrin holds an M.D. from the University of Ljubljana, Slovenia and was a Fellow at the University of Michigan Medical School.